

## **Supplemental Information**

### **Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma**

**Yi Shi, Dan-Dan Zhang, Ji-Bin Liu, Xiao-Li Yang, Rui Xin, Cheng-You Jia, Hui-Min Wang, Gai-Xia Lu, Pei-Yao Wang, Yu Liu, Zi-Jin Li, Jing Deng, Qin-Lu Lin, Liang Ma, Shan-Shan Feng, Xiao-Qi Chen, Xiang-Min Zheng, Ya-Fu Zhou, Yong-Jun Hu, Hua-Qun Yin, Lin-Lin Tian, Li-Peng Gu, Zhong-Wei Lv, Fei Yu, Wen Li, Yu-Shui Ma, and Fu Da**

**Table. S1. Immunohistochemistry of PTEN in Human Protein Atlas database.**

No.	Tissue type	ID	Age	Gender	Staining
1	normal	1720	67	male	low
2	normal	3402	54	female	low
3	tumor	879	70	male	not detected
4	tumor	2766	73	female	not detected

**Table. S2. Univariate analysis of overall survival in HCC patients stratified based on clinical characteristics.**

Factor	Variable	N	DLEU2L		TAOK1		Overall survival			P value (Log-rank test)	
			Expression (Median)	P value	Expression (Median)	P value	Months (Median)	95% CI (mean)			
Age	≥60	200	0.012	0.863	1.907	0.463	52.63	58.00-74.86	0.272		
	<60	169	0.012		2.019		46.33	58.20-76.71			
Gender	Male	248	0.011	0.046	1.866	0.01	47.67	58.00-72.60	0.257		
	Female	121	0.014		2.15		52.67	58.48-81.88			
Diameter	>5	94	0.018	<b>0.031</b>	2.072	<b>0.029</b>	34.33	43.98-67.49	<b>&lt;0.0001</b>		
	≤5	272	0.011		1.907		52.54	63.64-78.29			
Lymph-node metastasis	Negative	251	0.011	0.161	2.019	0.004	48.92	64.09-80.31	0.071		

	Positive	4	0.044		3.5		54.38	-133.6	
	Unknown	113	0.013		1.807		49.67	46.57-64.47	
Distant metastasis	Negative	265	0.011	0.159	1.999	0.742	48.75	62.61-78.37	0.003
	Positive	4	0.003		2.107		2.257	-38.27	
TNM stage	Unknown	100	0.013		1.887		50.96	49.42-67.85	
	I-II	255	0.011	<b>0.048</b>	1.887	<b>0.032</b>	50.67	63.71-79.07	<b>&lt;0.0001</b>
BMI	III-IV	90	0.019		2.082		34.17	43.61-68.27	
	Unknown	24	0.012		2.037		61.29	42.62-77.94	
Age	<18.5	21	0.015	0.893	1.955	0.653	48.92	35.11-108.1	0.093
	18.5-23.9	136	0.011		2.068		39.04	47.95-66.00	
	24-27.9	82	0.011		1.889		53.63	65.82-95.92	
	≥28	94	0.012		1.83		59.25	62.70-86.87	

**Table. S3. Univariate and Multivariate analysis (Cox regression model) of DLEU2L in HCC patients.**

Factor	Univariate Cox			Munivariate Cox		
	HR	95% CI	P value (Log-rank test)	HR	95% CI	P value (Log-rank test)
Age	1.216	0.857-1.725	0.273			
Gender	1.227	0.861-1.748	0.258			
TNM stage	1.791	1.415-2.269	0			
Diameter	2.208	1.605-3.037	0	2.14	1.553-2.949	0
Lymph-node metastasis	1.231	1.025-1.479	0.026			
Distant metastasis	1.273	1.058-1.531	0.01	1.276	1.060-1.536	0.01
BMI	1.034	0.880-1.216	0.683			
DLEU2L expression (high/low)	1.572	1.110-2.226	0.011	1.369	0.965-1.943	0.078

**Table. S4. Univariate and Multivariate analysis (Cox regression model) of TAOK1 in HCC patients.**

Factor	Univariate Cox			Munivariate Cox		
	HR	95% CI	P value (Log-rank test)	HR	95% CI	P value (Log-rank test)
Age	1.216	0.857-1.725	0.273			
Gender	1.227	0.861-1.748	0.258			
TNM stage	1.791	1.415-2.269	0			
Diameter	2.208	1.605-3.037	0	2.245	1.634-3.085	0
Lymph-node metastasis	1.231	1.025-1.479	0.026			
Distant metastasis	1.273	1.058-1.531	0.01	1.325	1.099-1.597	0.003
BMI	1.034	0.880-1.216	0.683			
DLEU2L expression (high/low)	1.537	1.085-2.177	0.016	1.622	1.141-2.306	0.007

**Table. S5. Correlation analysis betweenTAOK1 and biomarkers of Dendritic cell, Th1, Th2, Th17, and Treg in HCC in GEPIA.**

<b>Description</b>	<b>Gene markers</b>	<b>LIHC</b>	
		<b>Cor</b>	<b>P value</b>
Dendritic cell	BDCA-4 (NRP1)	0.51	0
Th1	STAT1	0.34	2e-13
Th2	STAT6	0.47	0
Th17	STAT3	0.63	0
Treg	STAT5B	0.65	0

**Table. S6. Correlation analysis between TAOK1 and biomarkers of immune cells using TIMER.**


Description	Gene markers	LIHC	
		Cor	Pvalue
CD8+ T cell	CD8A	-0.059	0.607
	CD8B	-0.123	0.279
T cell (general)	CD3D	-0.074	0.518
	CD3E	-0.169	0.137
	CD2	-0.202	0.075
B cell	CD19	0.027	0.815
	CD79A	-0.16	0.158
Monocyte	CD86	-0.022	0.845
	CD115 (CSF1R)	-0.128	0.261
TAM	CCL2	-0.06	0.601
	CD68	0.041	0.716
	IL10	-0.009	0.938
M1 Macrophage	INOS (NOS2)	0.144	0.204
	IRF5	0.118	0.298
	COX2 (PTGS2)	0.213	0.059
M2 Macrophage	CD163	0.119	0.295
	VSIG4	-0.051	0.655
	MS4A4A	-0.062	0.587
Neutrophils	CD66b (CEACAM8)	-0.247	<b>0.028</b>
	CD11b (ITGAM)	-0.031	0.783

	CCR7	0.022	0.849
Natural killer cell	KIR2DL1	-0.08	0.483
	KIR2DL3	-0.147	0.195
	KIR2DL4	-0.179	0.114
	KIR3DL1	0.026	0.819
	KIR3DL2	-0.228	<b>0.043</b>
	KIR3DL3	-0.152	0.181
	KIR2DS4	0.018	0.872
Dendritic cell	HLA-DPB1	-0.044	0.697
	HLA-DQB1	-0.076	0.505
	HLA-DRA	-0.044	0.698
	HLA-DPA1	-0.076	0.507
	BDCA-1 (CD1C)	0.02	0.863
	<b>BDCA-4 (NRP1)</b>	0.449	***
	CD11c (ITGAX)	0.111	0.328


Th1	T-bet (TBX21)	-0.103	0.366
	STAT4	0.059	0.603
	<b>STAT1</b>	0.405	**
	IFN- $\gamma$ (IFNG)	0.042	0.714
	TNF- $\alpha$ (TNF)	-0.12	0.294
Th2	GATA3	0.14	0.217
	<b>STAT6</b>	0.498	***
	STAT5A	0.266	<b>0.018</b>
	IL13	0.193	0.089
Tfh	BCL6	0.373	**
	IL21	NA	NA
Th17	<b>STAT3</b>	0.594	***
	IL17A	0.106	0.35
Treg	FOXP3	0.118	0.298
	CCR8	0.256	<b>0.023</b>
	<b>STAT5B</b>	0.461	***
	TGF $\beta$ (TGFB1)	0.145	0.202
T cell exhaustion	PD-1 (PDCD1)	-0.127	0.267
	CTLA4	-0.069	0.547
	LAG3	-0.089	0.436
	TIM-3 (HAVCR2)	0.044	0.699
	GZMB	-0.339	*

\*P<0.01, \*\* P<0.001, \*\*\* P<0.0001.

## Supplemental figure and legends.




**Fig. S1. Expression distribution expression of PTEN in various normal tissues.**




**Fig. S2. Volcano plots and heatmap plots of DElncRNAs, DEMiRNAs, and DEmRNAs between HCC samples and adjacent nontumor samples.** Red indicates upregulated genes, and blue indicates downregulated genes. The volcano plots described (A) 3371DElncRNAs ( $| \log_2 \text{Fold- Change} | > 0.5$  and adjusted p value  $< 0.05$ ), (B) 422DEMiRNAs ( $| \log_2 \text{FoldChange} | > 0.3$  and adjusted p value  $< 0.05$ ), and (C) 8294DEmRNAs ( $| \log_2 \text{FoldChange} | > 0.7$  and adjusted p value  $< 0.05$ ). (D-F) The horizontal axis of the heatmap denotes


the samples, and the vertical axis of heatmap denotes 15 significant DEGs.




**Fig. S3. The distribution of 13 hub-RNAs expression value from the triple regulatory network in 50 paired HCC tissues.**




**Fig. S4. Verify the expression of TAOK1.** (A) Expression distribution of TAOK1 in pan-cancer cell lines. (B) The expression level of TAOK1 in the GSE41804 HCC cohort of 20 paired HCC samples.



**Fig. S5. The mutation status of TAOK1 in HCC.** (A) The distribution of TAOK1 genomic alterations in the TCGA HCC dataset is shown on the cBioPortal OncoPrint plot. The correlation analysis between TAOK1 copy number and mRNA expression are shown in point plot (B) and correlation plot (C).



**Fig. S6. Different methylated regions associated with TAOK1.** Different methylated regions associated with TAOK1 were presented by heatmap using MethSurv.



**Fig. S7. Functional enrichment analysis of TAOK.** Functional enrichment analysis (including GO and KEGG) of TAOK associated genes in HCC.